Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.
Surviving Pink: A Mother-Daughter Duo on Believing in Hope
January 9th 2020In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with breast cancer survivor Felicia Robinson, who recently wrote a book with her daughter on their personal experiences with the various aspects of a life-changing diagnosis.
Read More
Concurrent Chemoradiotherapy With Proton Radiation Reduces Short-Term Side Effects
January 7th 2020Concurrent chemoradiotherapy with proton radiation can reduce short-term side effects that caused unplanned hospitalizations, with similar disease-free and overall survival, compared with photon radiation.
Read More
Phase 3 GRAVITAS-301 Study Fails to Improve Overall Responses in GVHD
January 7th 2020The pivotal phase 3 GRAVITAS-301 study – designed to evaluate itacitinib in combination with corticosteroids in patients with treatment-naïve acute graft-versus-host disease – failed to meet its primary endpoint of improving overall response rates.
Read More
Phase 3 Interim Analysis Shows Improved Survival in Patients with Bladder Cancer
January 7th 2020Patients with previously untreated locally advanced or metastatic urothelial carcinoma treated with Bavencio and best supportive care as a first-line maintenance therapy experienced significantly longer survival.
Read More
Clinical Trial Participants May Fare Better Than Medicare Beneficiaries Treated with Zydelig
January 4th 2020Those with follicular lymphoma and chronic lymphocytic leukemia who were treated with Zydelig in the clinical setting experienced less favorable outcomes, compared with those treated in a clinical trial.
Read More
FDA Approves Lynparza as First-Line Maintenance Treatment for Metastatic Pancreatic Cancer
December 30th 2019The Food and Drug Administration approved the first PARP inhibitor for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma.
Read More
FDA Approves Padcev to Treat Bladder Cancer
December 19th 2019The Food and Drug Administration approved Padcev for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have received prior treatment with a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy.
Read More
MRD Measurement Shows Promise for Making Informed Treatment Decisions in Myeloma
December 15th 2019At CURE’s Educated Patient Summit on Multiple Myeloma, Dr. Barry Paul discussed the role of minimal residual disease measurement and how it may be used in the future to determine treatment options for patients with myeloma.
Read More
FDA Approves Frontline Tecentriq/Chemotherapy for Metastatic Non-Squamous NSCLC
December 4th 2019The Food and Drug Administration approved Tecentriq in combination with chemotherapy for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer without EGFR or ALK mutations.
Read More
FDA Grants Priority Review to Durvalumab for Extensive-Stage Small Cell Lung Cancer
December 3rd 2019The FDA accepted a supplemental biologics license application (sBLA) and granted a priority review to Imfinzi (durvalumab) for the treatment of patients with previously untreated extensive-stage small cell lung cancer (SCLC), according to AstraZeneca, the drug’s manufacturer.
Read More
FDA Grants Priority Review to Pemigatinib for Cholangiocarcinoma Treatment
December 3rd 2019The FDA has granted a priority review to a new drug application (NDA) for pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma – a cancer that originates in the bile ducts – with FGFR2 fusions or rearrangements, according to Incyte, the agent’s manufacturer.
Read More